Background: Diastolic dysfunction (DD) is an important cause of cardiovascular dis-
Introduction
Patients with chronic kidney disease (CKD) have a 30-fold increased risk of age-adjusted cardiovascular disease (CVD) mortality in comparison with the general population. 1, 2 Although atherosclerosis is the predominant cause of CVD-related mortality in the general population, non-atherosclerotic CVD, such as cardiac failure and sudden cardiac death (SCD), is responsible for approximately 30% of CVD-related mortality in CKD patients. 3 Left ventricular diastolic dysfunction (DD) is an early manifestation of non-atherosclerotic CVD, which precedes clinically overt cardiac failure in CKD patients. 4, 5 DD is more common than abnormal systolic function in CKD patients as demonstrated by the Chronic Renal Insufficiency Cohort (CRIC) study of 3939 stages 3-4 CKD patients in which 75% and 12% displayed echocardiographic evidence of DD and systolic dysfunction respectively. 6 CKD patients are also at increased risk of DD with an approximately threefold increased prevalence of severe DD (pseudo-normalisation and restrictive filling patterns) in comparison with the general population. 7, 8 Severe DD is an independent poor prognostic marker and is associated with a 10-and 2.9-fold increased risk of all-cause mortality in the general population and CKD patients respectively. 7, 8 The underlying pathology of DD involves myocardial fibrosis, which results in reduced cardiac compliance and manifests clinically as intolerance to even small changes in blood volume or other haemodynamic stressors. 5 The pathogenesis of myocardial fibrosis is not completely understood, particularly in CKD patients in whom cardiac mass and fibrosis is significantly increased in comparison with age-matched healthy subjects or those with diabetes or hypertension. 9 Both traditional risk factors, such as diabetes or hypertension, and non-traditional risk factors, such as arterial stiffness and chronic inflammation, are likely to be involved in the pathogenesis of DD, but the relative magnitude of their respective contributions to DD remains unclear in CKD patients. 5, [10] [11] [12] Arterial pulse pressure (PP) and highly sensitive Creactive protein (hsCRP) are surrogate markers of arterial stiffness and inflammation, respectively, which are associated with increased CVD mortality in CKD patients. 13, 14 Recent studies have suggested that serum hsCRP levels and PP index may be associated with increased risk of DD in CKD patients. 6, 15 Interleukin (IL)-12 and IL-18 are pro-inflammatory cytokines implicated in the development of atherosclerosis and are predictive of coronary events and CVD mortality in the general population. [16] [17] [18] CKD patients have 2-3-fold elevations in serum IL-12 and IL-18 levels compared with the general population. 19 Some, but not all, studies have suggested an association between IL-12 and IL-18 in CKD patients with CVD surrogate markers and all-cause mortality, but their relationship with DD has not previously been explored. [19] [20] [21] We hypothesised that increased serum concentrations of IL-12, IL-18, hsCRP and 24-h PP are associated with DD in CKD patients. The primary aim of this study was to evaluate the association between IL-12, IL-18, hsCRP and 24-h PP with DD in stages 3-4 CKD patients.
Methods
This was a sub-analysis of prospectively obtained samples from 78 participants in the Fish-CoQ Study (ACTRN12605000088640), a double-blinded, randomised, placebo-controlled trial examining the effects of fish oil and coenzyme Q10 on blood pressure and lipid profile in stages 3-4 CKD patients (Fig. 1) . The study design, methods, inclusion and exclusion criteria have previously been published. 22 Participants were recruited from nephrology units of three major tertiary hospitals in Perth, Western Australia. The main inclusion criteria were age between 25 and 75 years, serum creatinine <350 μmol/L and estimated glomerular filtration rate (eGFR) of 15- 
Exposure factors
The study exposure factors were pre-intervention mean 24-h PP (difference between the mean 24-h systolic blood pressure (SBP) and diastolic blood pressure (DBP)) and serum levels of IL-12, IL-18 and hsCRP.
Clinical outcomes
The primary outcome was the presence of preintervention DD. Secondary outcomes included the presence of pre-intervention severe DD (defined as grade II or III DD) and pre-specified diastolic parameters of left atrial volume index (LAVI) and the ratio of early mitral inflow to mitral annular velocity (E/e' ratio).
Measurement of pro-inflammatory cytokines
Serum IL-12 and IL-18 levels were measured using enzyme-linked immunosorbent (ELISA) kits (BD Biosciences, CA, USA; MBL Co. Ltd, Nagoya, Japan) according to manufacturer's instructions, with detection thresholds of 12.5 pg/mL and 7.8 pg/mL respectively. Intra-and inter-assay coefficients of variation for IL-12 and IL-18 were 7% and 8% respectively. Serum hsCRP was measured using BNII Systems (Siemens Healthcare Diagnostics Inc. Network, DE, USA), with a detection threshold of 0.175 mg/L.
Measurement of 24-h blood pressure (BP) and pulse pressure (PP)
20-and 30-min intervals during waking hours and sleep respectively. Mean 24-h PP was determined as the difference between mean 24-h SBP and DBP.
Measurement of cardiac parameters using echocardiography
Baseline transthoracic echocardiograms were performed by two dedicated cardiac technicians at a single site (Hollywood Private Hospital, Perth, WA, Australia) using the Acuson Sequioa Ultrasound System (Siemens, AG, Munich, Germany) with digital storage (KinetDx; Siemens AG). Measurements of cardiac volume, dimensions, systolic and diastolic function were performed according to standard guidelines from the American Society of Echocardiography. 24 Simpson's biplane method was used to calculate the left ventricular ejection fraction (LVEF). Left atrial volume was quantified by Simpson's 2D biplane method and indexed for body surface area. 25 Pulsed-wave Doppler techniques were used to measure pulmonary venous, transmitral inflow and mitral annular velocities in the apical four-chamber view. Data were collected as the mean of three measurements on separate cardiac cycles.
Grading of diastolic dysfunction
DD was categorised as normal, grade I (impaired relaxation), grade II (pseudo-normalisation) or grade III (restrictive) according to established criteria from the American Society of Echocardiography. Diagnosis of DD required the fulfilment of two or more echocardiographic criteria based on the ratio of early and late mitral inflow velocity (E/A), mitral annular velocity (e'), ratio of early mitral inflow to mitral annular velocity (E/e'), left atrial volume index (LAVI) and the difference between pulmonary venous atrial wave reversal duration and mitral A wave duration (Ar-A).
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Biochemical parameters
Fasting serum creatinine (μmol/L), total cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C; mmol/L), triglycerides (TG; mmol/L) and high-density lipoprotein cholesterol (HDL-C; mmol/L) levels were obtained from all participants. 22 Serum creatinine was measured through the Jaffe method. 26 
Statistical analysis
Baseline characteristics are presented as mean AE standard deviation (SD) for normally distributed data, geometric mean with 95% confidence interval (CI) for log-transformed (base e) data and median (interquartile range; IQR) for skewed variables. Comparisons of continuous variables were examined using student's ttest or Mann-Whitney U-test where appropriate. Comparisons of categorical variables were performed using Chi-squared (χ 2 ) test. The associations between the primary exposure factors and grades I-III DD were examined using adjusted logistic regression analysis, and results were reported as odds ratio (OR) with 95% CI. The associations between the primary exposure factors with individual parameters of DD (E/e' ratio and LAVI) were evaluated using linear regression analysis. Covariates (age, gender, medication use, history of previous CVD, waist : hip circumference, BMI, preintervention eGFR and pre-intervention cholesterol profile) with P < 0.05 in the univariate models were included in the multivariable-adjusted models. Pvalues of <0.05 in two-tailed testing were considered statistically significant. Statistical analyses were undertaken using SPSS version 18.0 for Windows (Statistical Package for Social Sciences, SPSS Inc., Chicago, IL, USA).
Results

Study population
The mean age was (55.3 AE 13.4) years, and 73% were male. Prevalent CVD and hypertension were present in 6 (7.6%) and 70 (90%) subjects respectively. At least 50% were on either statin and/or ACE-inhibitor/ARB therapy. The median (IQR) GFR was 38 (27-43) mL/min/1.73 m 2 , and 25 subjects (32%) had stage 4 CKD with a median (IQR) GFR of 22 (19) (20) (21) (22) (23) (24) (25) (26) (27) 
Characteristics of participants with DD
DD was present in 38 subjects (49%), with grades I, II and III DD present in 14 (18%), 21 (27%) and 3 (4%) of participants respectively. Compared to those without DD, subjects with DD were significantly older (61.0 AE 1.9 vs 50.2 AE 2.0 years.; P < 0.001) and were more likely to be male (84% vs 63%; P = 0.04). Subjects with DD had higher 24-h PP (48(95% CI 45, 52) vs 43(95% CI 41, 45); P = 0.004) but had similar serum levels of IL-12, IL-18 and hsCRP (Table 1) .
Association between 24-h PP and DD
There was a significant association between 24-h PP and DD in the unadjusted model (OR = 1.1; 95% CI 1.01, 1.13). This was no longer significant (OR = 1.03, 95% CI 0.97, 1.10) in the model adjusted for age (Table 2) .
In an unadjusted model, 24-h PP was significantly associated with severe DD (OR = 1.08, 95% CI 1.02, 1.15). This was no longer significant (OR = 1.06, 95% CI 0.99, 1.13) in a model adjusted for age (data not shown).
There was a significant association between 24-h PP and the E/e' ratio (B = 0.01; P = 0.005) in an unadjusted model. This relationship was no longer significant (B = 0.01; P = 0.08) in a model adjusted for age (data not shown). A significant association between 24-h PP and the LAVI (B = 0.01; P < 0.001) in an unadjusted model remained significant (B = 0.7; P < 0.001) after adjusting for age, previous CVD and BMI (data not shown).
Association between IL-12, IL-18 and hsCRP with DD
There were no significant associations between IL-12 (OR = 0.99; 95% CI 0.98, 1.01), IL-18 (OR = 0.99; 95% CI 0.98, 1.01) or hsCRP (OR = 0.98; 95% CI 0.86, 1.1) with DD in unadjusted or adjusted models (Table 2) .
There were no significant associations between IL-12 (OR = 1.0; 95% CI 0.98, 1.01), IL-18 (OR = 0.99; 95% CI 0.98, 1.0) or hsCRP (OR = 0.98; 95% CI 0.85, 1.1) and severe DD (Grades II and III) in unadjusted or adjusted models (data not shown).
There was no association between IL-12 and the E/e' ratio (B = (−0.04); P = 0.1) or the LAVI (B = (−0.01); P = 0.7) in the unadjusted models. There was no association between IL-18 and the E/e ratio (B = (−0.06), P = 0.1) or the LAVI (B = (−0.02); P = 0.6) in the unadjusted models. There was no association between hsCRP and the E/e' ratio (B = 0.03; P = 0.4) or the LAVI (B = 0.02; P = 0.5) in the unadjusted models. 
Discussion
Subclinical DD was present in almost 50% of patients with moderate CKD and was severe in over 60% of these patients. There was no association between proinflammatory cytokines and markers with DD, and 24-h PP was associated with LAVI and DD, but this was no longer significant after adjustment for age.
Our study findings are similar to other CKD cohorts that demonstrate a high prevalence of asymptomatic subclinical DD in CKD patients as well as a direct relationship between the incidence and severity of DD with incremental CKD stage. This has significant clinical implications given that no effective interventions for DD currently exist and highlights the importance of the early identification of DD as a potential opportunity for improved CVD risk stratification in CKD patients. 5 In a cohort of 300 CKD patients, the reported prevalence of DD was 55% and 70% in stages 3 and 4-5, respectively, and increased to 60% and 80% after 1-year follow up. 27 Similar findings have also been reported in other CKD cohorts. 28 Subclinical DD is also an established prognostic marker of poor outcomes in the general population and CKD patients. In a community study of 2402 participants from the general population, severe DD was associated with a 10-fold increased risk of all-cause mortality after adjustment for traditional risk factors. 8 Similarly, severe DD in a cohort of 129 chronic haemodialysis patients was associated with a 2.8-and 2.2-fold increased risk of mortality and CVD events respectively. 7 The association between age, PP and DD has reportedly been inconsistent, with cohort studies demonstrating both a lack of association between age and DD and that the association between PP and DD occurred independent of age. 15, 29 This lack of association may reflect dissimilar patient characteristics across study cohorts, which contribute to the uncertainty of the association between age and development of DD. Therefore, the generalisibility of study findings attempting to evaluate this association across cohorts of varying risk and characteristics may not be appropriate. However, it is biologically plausible that the relationship between age and DD is mediated through the same mechanisms as that for PP.
Nevertheless, this study adds to the body of knowledge regarding the relationship between arterial stiffness, PP and DD in CKD patients. There is a relative paucity of data about CKD, with only two studies having demonstrated a potential relationship between arterial stiffness and DD in patients with CKD and end-stage kidney disease respectively. 15, 30 This is clinically relevant as CKD is a disease population, with disproportionately increased CVD risk causing excess mortality and significant The utilisation of different methods to measure arterial stiffness and varying patient characteristics has also raised questions as to which measurement of arterial stiffness is optimally related to DD. In a community study of participants without CKD, aortic PWV had a stronger relationship with DD than peripherally measured PP. 29 Aortic PWV is considered the gold-standard non-invasive measurement of large artery stiffness, whereas peripheral PP is potentially influenced by other factors, such as heart rate, height and properties of the peripheral arteries. 13, 29, 32 A positive relationship between DD and clinicmeasured PP index has also recently been reported in a cohort of 511 patients with stages 3-4 CKD. 15 Significant differences between our study cohorts in terms of age, diabetes, blood pressure, use of ACE/ARB, assessment of PP (24 h-PP versus clinic PPI) and diagnostic criteria for DD could also account for our conflicting results. There is evidence that specific anti-hypertensive classes, such as ACE inhibitors/angiotensin receptor blockers and calcium channel blockers, preferentially lower central blood pressure, PP and arterial stiffness. 33 However, there was no association between the class of anti-hypertensive agent and 24-h PP in this study.
Chronic inflammation is associated with increased CVD in CKD patients, with each increment in serum hsCRP being associated with a 1.21-fold increased risk of CVD mortality in chronic dialysis patients.
14,34 IL-12 and IL-18 are pro-atherogenic cytokines that are associated with increased CVD risk in the general population and are present at elevated concentrations in the sera of CKD patients. 16, 17, 19 However, evidence is conflicting as to whether IL-12 and IL-18 are similarly associated with CVD in CKD patients, and their relationship with DD in this population has also not previously been explored. 19, 21 Inflammation is implicated in the pathogenesis of DD as part of a reactive immunological response to persistent cardiomyocyte injury, resulting in the release of pro-fibrotic factors, such as transforming growth factor (TGF)-β. 12 In contrast to our study findings, the CRIC study reported a 1.14-fold increased risk of DD with serum hsCRP levels but not other proinflammatory cytokines traditionally associated with atherosclerosis, such as IL-6. 6 Serum hsCRP levels were slightly lower in our cohort (mean < 2 g/L) compared to the CRIC cohort (mean 2-3 g/L), whereas IL-12 and IL-18 levels were similar to those published in other CKD cohorts. 19 The relationship between inflammation and DD may also potentially have been modified by the cardio-protective and anti-inflammatory effects of statins or ACE/ARB, which were prescribed to over 80% of our cohort. 35, 36 Finally, failure to demonstrate a relationship between pro-atherogenic cytokines and DD in our studies could also reflect the separate and independent disease biology of DD from that of atherosclerosis. 5, 37 Limited sample size and short follow-up period may have led to erroneous inferences and therefore we were unable to generate reliable estimates with certainty. The exclusion of participants with diabetes or current smoking may also have led to significant selection bias. Unmeasured confounders, such as duration of CKD or hypertension, may also have affected our findings.
Conclusion
Asymptomatic subclinical DD was present in 50% of a cohort of stages 3-4 CKD patients but was not associated with IL-12, IL-18 or hsCRP. The association between 24-h PP and DD was no longer apparent following adjustment for age, but given the small sample size, our findings will need to be explored in larger-sized cohorts of individuals with moderate-stage CKD.
